Page 238 - Official Year Book 2020
P. 238
launched by Global Alliance forVaccines
and Immunisation (GAVI), the Coalition
for Epidemic Preparedness Innovation
(CEPI) and the World Health Organization
(WHO) to provide equitable access
globally for diagnostics, treatment and
vaccines. Participation in this facility
guarantees the supply of vaccines for
10 percent of those living in Malaysia.
The Governments of Malaysia and the
People’s Republic of China have signed
an agreement on their cooperation for
the safe and efficacious development
of vaccines on 18 November 2020.
This agreement serves as a platform
to provide Malaysia priority access to
the COVID-19 vaccines developed by
the People’s Republic of China. Apart
from that, it will facilitate expertise
and knowledge sharing, as well as
facilitate cooperation in the fields
of science and technology between
the two countries, in line with the
aspiration to develop the vaccine
industry of both nations.
O234 FFICIAL YEAR BOOK 2020 The Government also negotiated with the national supply of vaccines. This
COVID-19 vaccine manufacturers to includes the development of vaccine
look at not only the technical aspects bottling (fill and finish), Research
such as durability, development, and Development (R&D) as well as
methods, stability, contraindications, technology transfer and vaccine
population target, safety, manufacturing in the future.
effectiveness, dosage, registration
and access, but also the commercial
aspects of the vaccine such as pricing,
refunds, delivery schedule, advance
payment as well as logistics.
Apart from that, the negotiations
also cover aspects of cooperation
and value add to the development of
and Immunisation (GAVI), the Coalition
for Epidemic Preparedness Innovation
(CEPI) and the World Health Organization
(WHO) to provide equitable access
globally for diagnostics, treatment and
vaccines. Participation in this facility
guarantees the supply of vaccines for
10 percent of those living in Malaysia.
The Governments of Malaysia and the
People’s Republic of China have signed
an agreement on their cooperation for
the safe and efficacious development
of vaccines on 18 November 2020.
This agreement serves as a platform
to provide Malaysia priority access to
the COVID-19 vaccines developed by
the People’s Republic of China. Apart
from that, it will facilitate expertise
and knowledge sharing, as well as
facilitate cooperation in the fields
of science and technology between
the two countries, in line with the
aspiration to develop the vaccine
industry of both nations.
O234 FFICIAL YEAR BOOK 2020 The Government also negotiated with the national supply of vaccines. This
COVID-19 vaccine manufacturers to includes the development of vaccine
look at not only the technical aspects bottling (fill and finish), Research
such as durability, development, and Development (R&D) as well as
methods, stability, contraindications, technology transfer and vaccine
population target, safety, manufacturing in the future.
effectiveness, dosage, registration
and access, but also the commercial
aspects of the vaccine such as pricing,
refunds, delivery schedule, advance
payment as well as logistics.
Apart from that, the negotiations
also cover aspects of cooperation
and value add to the development of
